BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260728
DTEND;VALUE=DATE:20260731
DTSTAMP:20260515T001418
CREATED:20260312T131240Z
LAST-MODIFIED:20260312T131240Z
UID:43114-1785196800-1785455999@www.pharmajournalist.com
SUMMARY:4th ADC Linker & Conjugation Summit
DESCRIPTION:4th ADC Linker & Conjugation Summit\nLinking Chemistry to Clinical Success Through Better ADC Design \n\nWhen? July 28-30\, 2026\nWhere? Boston\, MA\n\nADC development is evolving fast\, with developers pushing beyond traditional cytotoxins into dual‑payload constructs\, high‑DAR species\, degrader–antibody conjugates\, and next‑generation modalities. This surge in innovation is placing new pressure on linker architecture and conjugation chemistry to improve stability\, reduce off‑target toxicity\, and maintain manufacturability at scale. \nThe 4th ADC Linker & Conjugation Summit returns this July as the only meeting dedicated exclusively to overcoming these chemistry‑centric challenges. Built specifically for ADC chemists\, protein engineers\, and bioconjugation specialists\, the summit offers a highly curated setting where every session speaks directly to the scientific bottlenecks shaping next‑generation ADC performance. Attendees join peers with the same technical focus\, ensuring every conversation is relevant and grounded in real‑world ADC development needs.Across three focused days\, more than 80 scientific experts will dissect the mechanisms driving linker stability\, conjugation precision\, and payload behavior. The program features 20+ industry‑led case studies covering homogeneous ADC design\, controlling premature payload release\, dual‑payload engineering\, hydrophobicity‑driven aggregation\, and the integration of predictive modeling into conjugation strategies. These sessions reflect broader industry priorities\, where site‑specific conjugation\, next‑generation linkers\, and stability optimization remain top areas of innovation. \nThis year introduces expanded workshops and interactive debates\, including new sessions examining how to more effectively connect linker chemistry to translational outcomes and how to redesign payloads using emerging linker technologies. The 2026 meeting also welcomes 17 new speakers from 13 new companies\, offering fresh insight into the rapidly diversifying toolkit available for ADC design. \nFor scientists working at the core of ADC chemistry\, this summit provides a rare opportunity to benchmark strategies\, challenge assumptions\, and contribute to the next decade of linker and conjugation innovation. \nView the full program and explore the 2026 agenda \nDownload the event guide here: https://ter.li/7pj7r6
URL:https://www.pharmajournalist.com/event/4th-adc-linker-conjugation-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260728
DTEND;VALUE=DATE:20260731
DTSTAMP:20260515T001418
CREATED:20260326T114512Z
LAST-MODIFIED:20260326T114512Z
UID:43226-1785196800-1785455999@www.pharmajournalist.com
SUMMARY:5th In Vivo Cell Engineering & Gene Editing Summit
DESCRIPTION:The 5th In Vivo Cell Engineering & Gene Editing Summit returns as the leading industry meeting dedicated to advancing the next generation of in vivo delivery platforms\, gene editing tools\, and translational strategies that support safe\, precise\, and scalable genetic medicines. Designed for scientists\, technical leaders\, and strategic decision-makers across biopharma\, this summit provides a focused forum to exchange practical insights that directly influence scientific and clinical progress. \nThis year’s faculty brings together experts from cutting-edge biotechnology companies and global pharmaceutical organizations\, including leaders from AstraZeneca\, Pfizer\, Eli Lilly\, Ensoma\, Capstan Therapeutics\, Verve Therapeutics\, nChrioma Bio\, and more. Their collective experience spans delivery system innovation\, payload engineering\, translational development\, and early clinical execution\, giving delegates a clear view of what is required to successfully advance in vivo platforms. \nOver three days of data-driven discussion\, attendees will explore the latest advancements in lipid nanoparticle engineering\, viral and nonviral vector optimization\, capsid evolution\, and emerging delivery technologies for targeted\, efficient editing. Sessions will detail how teams are engineering payloads to enhance potency\, durability\, safety\, and manufacturability. Speakers will also share frameworks for designing rigorous preclinical packages that address biodistribution\, immunogenicity\, and off-target risk early in development. \nThe summit places a strong focus on translational and early clinical learnings\, with case studies that reveal how organizations are approaching dose selection\, biomarker development\, patient monitoring\, and regulatory positioning. These insights provide an unfiltered look at what has worked in real programs and how teams are adjusting strategies to improve clinical readiness. \nDelegates will benefit from a mix of scientific depth and strategic clarity. Whether you are building new delivery platforms\, advancing editing tools\, refining analytical approaches\, or preparing a therapy for first-in-human studies\, this meeting helps you benchmark your progress and sharpen decision-making. \nJoin peers who are driving the future of in vivo gene editing and cell engineering. This summit delivers the connections\, evidence-based insights\, and collaborative environment needed to progress transformative genetic medicines. \nTo learn more and register online\, please click here.
URL:https://www.pharmajournalist.com/event/5th-in-vivo-cell-engineering-gene-editing-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR